Skip to main content
Premium Trial:

Request an Annual Quote

Evotec OAI, Evotec Neurosciences, Chemicon International


Evotec OAI Buys Spin-Off Evotec Neurosciences; Raises €27M in VC Cash

Evotec OAI said this week that it has acquire the remaining 78 percent of spin-off company Evotec Neurosciences not already owned by Evotec OAI.

The acquisition will constitute a share-for-share exchange transaction in which Evotec will issue approximately 14.3 million new ordinary shares, the company said. Evotec also said that the transaction is valued at €49 million (US $64.7 million).

Evotec said that the acquisition was intended to further develop and expand its drug-discovery contract research business. Evotec Neurosciences discovers and develops therapeutics for the treatment of Alzheimer’s disease and other CNS disorders.

The company also said that it has received a commitment from a new group of investors to purchase 10 million new ordinary shares of Evotec priced at €2.72 each, for a total of about €27 million in equity investment.

Evotec OAI is traded on the Frankfurt Stock Exchange under the ticker symbol “EVT.” It also has a subsidiary, Evotec Technologies, which markets a variety of instrumentation, including the Opera high-content screening platform, for drug discovery.

Serologicals Subsidiary to Market Quantum Dot Technology

Chemicon International, a subsidiary of Serologicals, will market specific quantum dot-containing products from Quantum Dot for the detection of antibody-antigen interactions in immunological experiments, the companies said last week.

The firms said the agreement will “add novel secondary antibody detection technologies to Chemicon’s general reagents product portfolio,” enabling researchers to study antigen presence in a variety of tissue and cell culture samples.

Chemicon will sell these products under the Chemicon brand through its direct sales team in North America, Australia, UK, and “much of Europe,” as well as through its worldwide network of distributors, the companies said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.